Form 4: UNITED THERAPEUTICS Executive Sells Shares
Insider Transaction (Form 4)
Paul A Mahon, EVP & GENERAL COUNSEL of UNITED THERAPEUTICS Corp, sold 8,300 shares of common stock on October 1, 2026.
Summary
- Option exercise/conversion: acquired 8,300 Common Stock at $146.03 ($1,212,049) on October 1, 2026; holds 53,472 after (Direct).
- Open-market sale: disposed of 880 Common Stock at $558.30 ($491,308) on October 1, 2026; holds 52,592 after (Direct).
- Open-market sale: disposed of 1,480 Common Stock at $560.19 ($829,083) on October 1, 2026; holds 51,112 after (Direct).
- Open-market sale: disposed of 780 Common Stock at $561.87 ($438,259) on October 1, 2026; holds 50,332 after (Direct).
- Open-market sale: disposed of 1,480 Common Stock at $563.09 ($833,374) on October 1, 2026; holds 48,852 after (Direct).
- Open-market sale: disposed of 400 Common Stock at $566.41 ($226,562) on October 1, 2026; holds 48,452 after (Direct).
- Open-market sale: disposed of 720 Common Stock at $567.76 ($408,788) on October 1, 2026; holds 47,732 after (Direct).
- Open-market sale: disposed of 739 Common Stock at $569.15 ($420,600) on October 1, 2026; holds 46,993 after (Direct).
- Open-market sale: disposed of 838 Common Stock at $570.90 ($478,411) on October 1, 2026; holds 46,155 after (Direct).
- Open-market sale: disposed of 823 Common Stock at $572.25 ($470,961) on October 1, 2026; holds 45,332 after (Direct).
- Open-market sale: disposed of 160 Common Stock at $573.15 ($91,704) on October 1, 2026; holds 45,172 after (Direct).
- Option exercise/conversion: disposed of 8,300 Stock Option on October 1, 2026; holds 39,240 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $4,689,051 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Paul A Mahon — Officer (EVP & GENERAL COUNSEL)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-01 | Option exercise/conversion | Common Stock | 8,300 | $146 | $1.2M | 53,472 |
| 2026-10-01 | Open-market sale | Common Stock | 880 | $558 | $491.3K | 52,592 |
| 2026-10-01 | Open-market sale | Common Stock | 1,480 | $560 | $829.1K | 51,112 |
| 2026-10-01 | Open-market sale | Common Stock | 780 | $562 | $438.3K | 50,332 |
| 2026-10-01 | Open-market sale | Common Stock | 1,480 | $563 | $833.4K | 48,852 |
| 2026-10-01 | Open-market sale | Common Stock | 400 | $566 | $226.6K | 48,452 |
| 2026-10-01 | Open-market sale | Common Stock | 720 | $568 | $408.8K | 47,732 |
| 2026-10-01 | Open-market sale | Common Stock | 739 | $569 | $420.6K | 46,993 |
| 2026-10-01 | Open-market sale | Common Stock | 838 | $571 | $478.4K | 46,155 |
| 2026-10-01 | Open-market sale | Common Stock | 823 | $572 | $471.0K | 45,332 |
| 2026-10-01 | Open-market sale | Common Stock | 160 | $573 | $91.7K | 45,172 |
| 2026-10-01 | Option exercise/conversion | Stock Option | 8,300 | — | — | 39,240 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-01 | Option exercise/conversion (8,300 shares) |
| 2026-10-01 | Open-market sale (880 shares) |
| 2026-10-01 | Open-market sale (1,480 shares) |
| 2026-10-01 | Open-market sale (780 shares) |
| 2026-10-01 | Open-market sale (1,480 shares) |
| 2026-10-01 | Open-market sale (400 shares) |
| 2026-10-01 | Open-market sale (720 shares) |
| 2026-10-01 | Open-market sale (739 shares) |
| 2026-10-01 | Open-market sale (838 shares) |
| 2026-10-01 | Open-market sale (823 shares) |
| 2026-10-01 | Open-market sale (160 shares) |
| 2026-10-01 | Option exercise/conversion (8,300 shares) |
Keywords
insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Paul A Mahon
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.